Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.66 USD
-0.03 (-1.78%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.65 -0.01 (-0.60%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXRX 1.66 -0.03(-1.78%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Other News for LXRX
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Lexicon Pharmaceuticals announces departure of President, COO Jeff Wade
Lexicon announces departure of President, COO Jeff Wade
Lexicon Pharmaceuticals Announces Executive Leadership Changes
Lexicon management to meet with Piper Sandler